{
  "id": 3585366,
  "title": "Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026",
  "url": "https://urgent.news/2026/08/26/xenon-to-highlight-phase-3-x-tole2-clinical-data-and-rational",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T20:03:09.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/xenon-to-highlight-phase-3-x-tole2-clinical-data-and-rational-polytherapy-potential-for-azetukalner-at-eec-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with commonly prescribed ASMs VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}